country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-137996

Copy Link Print Information

Dehydrovomifoliol

Avis client

Based on 1 Customer Validation

Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.88%
CAS No.: 39763-33-2
Formule: C₁₃H₁₈O₃
Masse moléculaire:222.28

Stockage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Dehydrovomifoliol Chemical Structure

CAS No.: 39763-33-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform mTOR :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>64.4 μM Compound: 12	Cytostatic activity against human A549 cells after 48 cells by MTT assay Cytostatic activity against human A549 cells after 48 cells by MTT assay	[PMID: 21561060]
C8166	CC₅₀	>450.5 μM Compound: 12	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 21561060]
C8166	EC₅₀	>450.5 μM Compound: 12	Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay	[PMID: 21561060]
HL-60	IC₅₀	>64.4 μM Compound: 12	Cytostatic activity against human HL60 cells after 48 cells by MTT assay Cytostatic activity against human HL60 cells after 48 cells by MTT assay	[PMID: 21561060]
HT-29	IC₅₀	>10 μM Compound: S7	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
HT-29	IC₅₀	>10 μM Compound: S7	Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay	[PMID: 30057155]
MCF7	IC₅₀	>64.4 μM Compound: 12	Cytostatic activity against human MCF7 cells after 48 cells by MTT assay Cytostatic activity against human MCF7 cells after 48 cells by MTT assay	[PMID: 21561060]
MDA-MB-435	IC₅₀	>10 μM Compound: S7	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
OVCAR-3	IC₅₀	>10 μM Compound: S7	Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30057155]
RAW264.7	IC₅₀	>50 μM Compound: 10	Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA	[PMID: 24963714]
RAW264.7	IC₅₀	>64.4 μM Compound: 12	Antiinflammatory against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production Antiinflammatory against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production	[PMID: 21561060]
RAW264.7	IC₅₀	38.5 μM Compound: 10	Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay	[PMID: 24963714]
SMMC-7721	IC₅₀	>64.4 μM Compound: 12	Cytostatic activity against human SMMC7721 cells after 48 cells by MTT assay Cytostatic activity against human SMMC7721 cells after 48 cells by MTT assay	[PMID: 21561060]
SW480	IC₅₀	>64.4 μM Compound: 12	Cytostatic activity against human SW480 cells after 48 cells by MTT assay Cytostatic activity against human SW480 cells after 48 cells by MTT assay	[PMID: 21561060]

Chemical Information

CAS No. 39763-33-2
Appearance Oil
Masse moléculaire 222.28
Formule C₁₃H₁₈O₃
Color Colorless to light yellow
SMILES

CC(/C=C/[C@](C(C)(C1)C)(C(C)=CC1=O)O)=O
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (267 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Ma J, et al. Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study. Evid Based Complement Alternat Med. 2023 Feb 1;2023:9107598. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
Chemical Information
Pureté et documentation
Références

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Dehydrovomifoliol

Voir tous les produits spécifiques à Isoform Akt

Voir tous les produits spécifiques à Isoform mTOR

Activité biologique

Chemical Information

Pureté et documentation

Références

Calculators

Help & FAQs

Dehydrovomifoliol Related Classifications

HY-137996 Related Classifications